ELIGO BIOSCIENCE
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
ELIGO BIOSCIENCE
Industry:
Biotechnology Health Care Medical
Founded:
2014-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.eligo.bio
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
39.81 M USD
Technology used in webpage:
SPF SSL By Default Euro IPv6 Google Apps For Business US Privacy User Signal Mechanism Google Google Cloud Cloudflare Hosting Cloudflare DNS
Current Advisors List
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Eligo Bioscience
European Commission
European Commission investment in Grant - Eligo Bioscience
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Eligo Bioscience
Seventure Partners
Seventure Partners investment in Series A - Eligo Bioscience
Khosla Ventures
Khosla Ventures investment in Series A - Eligo Bioscience
Worldwide Innovation Challenge
Worldwide Innovation Challenge investment in Grant - Eligo Bioscience
Seventure Partners
Seventure Partners investment in Seed Round - Eligo Bioscience
Worldwide Innovation Challenge
Worldwide Innovation Challenge investment in Seed Round - Eligo Bioscience
AGORANOV
AGORANOV investment in Angel Round - Eligo Bioscience
Official Site Inspections
http://www.eligo.bio Semrush global rank: 5.77 M Semrush visits lastest month: 1.45 K
- Host name: 172.67.153.39
- IP address: 172.67.153.39
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Eligo Bioscience"
Senior In Vivo Scientist - Microbiologist - Eligo Bioscience
Eligo Bioscience, backed by top-tier investors from Silicon Valley and Europe, is pioneering next-generation microbiome therapeutics. Co-founded by MIT and Rockefeller University scientists, …See details»
Eligo | Meet the Eligonauts - Eligo Bioscience
Cofounder & Advisor • Associate Professor at MIT • Cofounder & CEO Senti Bio • Cofounder Synlogic, Tango, Engine • NIH New Innovator Award, MIT TR35See details»
Eligo Bioscience - LinkedIn
Eligo Bioscience | 12,299 followers on LinkedIn. Precision medicines for the microbiome | Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome ...See details»
Eligo Bioscience - Crunchbase Company Profile
Eligo Bioscience may be growing as it has recently raised significant capital, specifically a $30 million investment, which indicates a strong financial influx …See details»
Eligo Bioscience Raises $30 Million To Write a Novel …
Dec 5, 2023 Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, ha Eligo Bioscience Raises $30 Million To Write ...See details»
Paris-based Eligo Bioscience raises €27.7 million Series …
Dec 5, 2023 Eligo Bioscience, a pioneering gene-editing company focused on addressing diseases driven by the expression of bacterial genes from the microbiome, has announced a successful €27.7 million Series B funding …See details»
Eligo Bioscience SA - Drug pipelines, Patents, Clinical trials - Synapse
Apr 1, 2025 Explore Eligo Bioscience SA with its drug pipeline, therapeutic area, technology platform, 20 news, Disease Domain:Infectious Diseases, Hemic and Lymphatic Diseases, …See details»
Careers | Head of People & HR - Eligo Bioscience
– A thoughtful, culture-driven leader with a deep interest in people operations & HR, eager to adapt and tailor best practices to meet the specific needs of our organization and the …See details»
Eligo Bioscience secures $30M Series B for its …
Dec 8, 2023 This is a defining time for Eligo as this funding puts us in a strong position to make a significant leap in treating diseases by editing the genetic makeup of the human microbiome.” This funding is earmarked for accelerating …See details»
Eligo Bioscience (fka PhageX) - VentureRadar
"Eligo is developing a new class of targeted biotherapeutic agents to selectively intervene on the microbiome. We are using proprietary methods in synthetic biology, protein and genome …See details»
Company: Eligo Bioscience - CRISPR Medicine
Website: https://eligo.bio/ Gene editing partnerships: GlaxoSmithKline. Eligo Biosciences seeks to perform precision editing of the human microbiome in order to treat infectious diseases. The …See details»
Eligo Bioscience Publishes Landmark Study in Nature
Jul 10, 2024 Paris, FRANCE – April 14 2025 – Eligo Bioscience, a biotechnology company pioneering the development of novel genetic medicines, today announced it has secured a $5 …See details»
Eligo Publishes in Nature a Landmark Study That Unlocks Genome …
PARIS, July 10, 2024 /PRNewswire/ -- For the first time, a team of scientists at Eligo has demonstrated it was possible to genetically modify bacteria with nearly 100% efficiency directly …See details»
Eligo Bioscience Company Information - Funding, Investors, and …
Key Insights: Eligo Bioscience December 2023 Series B Funding Round: $30m Eligo Bioscience April 2018 Series A Funding Round: $1.9m Eligo Bioscience September 2017 Series A …See details»
Eligo Bioscience Raises $30 Million To Write a Novel Chapter for ...
Dec 5, 2023 Contact: [email protected] About Sanofi Ventures Sanofi Ventures is the corporate venture capital arm of Sanofi. Sanofi Ventures invests in early-stage biotech and digital health …See details»
Eligo Bioscience Announces Successful Outcome in US Patent …
PARIS, Dec. 2, 2021 /PRNewswire/ -- Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement …See details»
Eligo Bioscience Publishes Landmark Study in Nature
Jul 10, 2024 Jesus Fernandez, Eligo VP of Technology and a senior author of the study, highlights how “ this achievement is the culmination of eight years of work by the team at Eligo …See details»
News & Press - Eligo Bioscience
Eligo unlocks next generation of precision genetic medicine with foundational patents granted covering in-situ base editing of the microbiome and presents first-ever animal data at CRISPR …See details»
Eligo | In vivo gene editing of the microbiome platform - Eligo …
Eligo develops first-in-class proprietary modalities that enable the delivery and expression of therapeutic DNA in target bacterial populations of the microbiome. This technology allows for …See details»